Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Chengdu Zenitar Biomedical Technology Co., Ltd clinical trials
The registry lists 23 studies whose lead sponsor is Chengdu Zenitar Biomedical Technology Co., Ltd. 12 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 16, 2026.
Keep track of what changes. Save the Chengdu Zenitar Biomedical Technology Co., Ltd studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesWhere
- China
- 22
Registry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Chengdu Zenitar Biomedical Technology Co., Ltd.
- Chengdu Zenitar Biomedical Technology Co., Ltd23 studiesSame company
Something wrong?
Studies
Recruiting first, then most recently updated. Showing 23 of 23.
- Flonoltinib Maleate Oral Regimens in Patients With MyelofibrosisNot yet recruitingNCT07750574Phase 2
- Mass Balance Study of [¹⁴C]Purinostat Mesylate for Injection in Healthy ParticipantsNot yet recruitingNCT07809217Phase 1
- Clinical Study on Drug Interactions of Flonoltinib Maleate TabletsNot yet recruitingNCT07768111Phase 1
- Phase IIa Study of Flonoltinib Maleate Tablets in the Treatment of Patients With Polycythemia VeraRecruitingNCT07232290Phase 2
- A Clinical Trial of Flonoltinib Maleate for Intermediate or High-Risk MyelofibrosisRecruitingNCT07317700Phase 3
- A Clinical Trial of Flonoltinib Maleate Tablets in the Treatment of JAK Inhibitor Refractory/Relapsed/Intolerant Patients With Intermediate to High Risk MyelofibrosisRecruitingNCT07443306Phase 2
- Phase I Clinical Study of ZL-65 Tablet in Healthy Adult Participants in ChinaRecruitingNCT07757152Phase 1
- A Phase II Clinical Study Evaluating of ZL-82 Tablets in Atopic DermatitisRecruitingNCT07193589Phase 2
- A Clinical Study of ZL-85FA TabletsNot yet recruitingNCT07339748Phase 1/2
- A Phase III Clinical Study of Purinostat Mesylate for Injection in Patients With Diffuse Large B-cell LymphomaRecruitingNCT07011056Phase 3
- A Clinical Study of Purinostat Mesylate for Injection in Patients With Advanced Solid TumorsRecruitingNCT06431243Phase 1/2
- Purinostat Mesylate Combined With Pomalidomide Capsules and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple MyelomaRecruitingNCT06484829Phase 1/2
- Study of Flonoltinib Maleate Tablets in the Treatment of Severe Novel Coronavirus (COVID-19) InfectionTerminatedNCT05713279Not applicable
- Mass Balance Study of [14C] Flonoltinib MaleateCompletedNCT07612306Phase 1
- A Phase II Clinical Trial of Flonoltinib Maleate Tablet in Intermediate-High Risk MyelofibrosisActive, not recruitingNCT06457425Phase 2
- A Phase IIa Clinical Study of Purinostat Mesylate for Injection in Patients With Peripheral T-Cell Lymphoma and Cutaneous T-Cell LymphomaActive, not recruitingNCT06485219Phase 2
- Study of Purinostat Mesylate for Injection in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)Active, not recruitingNCT05563844Phase 2
- Safety of Flonoltinib Maleate Tablets for the Treatment of Patients With MyeloproliferativeCompletedNCT05153343Phase 1/2
- Study of Purinostat Mesylate for Injection in the Treatment of Relapsed or Refractory B Cell-related Tumor-predominantCompletedNCT05526313Phase 1
- ZL-82 Double-blind Clinical TrialCompletedNCT06432738Phase 1
- A Pharmacokinetic Study of the Food Effect on Flonoltinib Maleate TabletsCompletedNCT07193576Phase 1
- A Phase I Clinical Study of Flonoltinib Maleate Tablets in Healthy SubjectsCompletedNCT06387966Phase 1
- Phase I Clinical Study of ZL-82 TabletsCompletedNCT06055023Phase 1